ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Employees: 54
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
688% more call options, than puts
Call options by funds: $961K | Put options by funds: $122K
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
43% more capital invested
Capital invested by funds: $13.5M [Q3] → $19.3M (+$5.83M) [Q4]
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
17% more funds holding
Funds holding: 75 [Q3] → 88 (+13) [Q4]
1.71% more ownership
Funds ownership: 6.95% [Q3] → 8.66% (+1.71%) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
652%
upside
Avg. target
$10
652%
upside
High target
$10
652%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 0% 1-year accuracy 0 / 41 met price target | 652%upside $10 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 7 articles about ATAI published over the past 30 days
Positive
Proactive Investors
5 days ago
atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.
Neutral
24/7 Wall Street
1 week ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Positive
Proactive Investors
2 weeks ago
atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update. “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
Positive
Proactive Investors
2 weeks ago
atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dosed its first patient in the Phase 2 Elumina trial for VLS-01, a buccal film formulation of DMT designed to treat treatment-resistant depression.
Positive
Proactive Investors
3 weeks ago
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression. Topline results are expected from the first treatment phase of the trial in the first quarter of 2026.
Neutral
GlobeNewsWire
3 weeks ago
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression
Positive
Proactive Investors
4 weeks ago
atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topline results expected by mid-2025. The trial is assessing the efficacy and safety of a single dose of BPL-003, an intranasal formulation of mebufotenin benzoate developed by Beckley Psytech, in which atai is invested, designed for rapid and lasting antidepressant effects with minimal clinic time.
Positive
Seeking Alpha
1 month ago
Atai: Following The Path That Spravato Laid And Moving Beyond It
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.
Neutral
GlobeNewsWire
1 month ago
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company's participation:
Neutral
24/7 Wall Street
1 month ago
Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
Charts implemented using Lightweight Charts™